Responses
Immunotherapy biomarkers
Original research
Molecular assessment of intratumoral immune cell subsets and potential mechanisms of resistance to odronextamab, a CD20×CD3 bispecific antibody, in patients with relapsed/refractory B-cell non-Hodgkin lymphoma
Compose a Response to This Article
Other responses
No responses have been published for this article.
